HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, announced that a peer-reviewed article in JACC: Advances demonstrated that a risk prediction algorithm incorporating its credit card-sized ECG device can accurately identify heart attack risk in patients presenting with chest pain. The proof-of-concept study evaluated 184 patients and found that the algorithm achieved an “area under the curve” (“AUC”) of 86.5% using a single HeartBeam ECG reading combined with patient risk factors and symptoms, rising to 92.9% when a personal, symptom-free baseline ECG was available for comparison.
These results support heart attack detection as a future indication for the HeartBeam System and advance its broader clinical program. The company’s 3D ECG technology, which received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025, is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians can identify cardiac health trends and acute conditions, directing patients to appropriate care outside of a medical facility.
For industry leaders, this development underscores the potential of portable, AI-enabled diagnostic tools to shift cardiac care from hospital settings to more accessible, cost-effective environments. The ability to accurately triage chest pain in emergency departments or even in remote settings could reduce unnecessary hospitalizations and accelerate treatment for those at risk. The study’s high AUC values suggest that the HeartBeam system could become a valuable tool for clinicians, potentially lowering healthcare costs and improving patient outcomes.
HeartBeam holds over 20 issued patents related to its technology, and the FDA clearance for arrhythmia assessment and 12-lead ECG synthesis marks a significant milestone in bringing its platform to market. The company’s focus on creating the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions positions it uniquely in the cardiac monitoring space.
For investors, these results may signal a growing validation of HeartBeam’s technology and its potential to capture a share of the cardiac diagnostic market. The study’s publication in a peer-reviewed journal adds credibility and could accelerate adoption among healthcare providers.
More information about HeartBeam’s cleared indications for use can be found at https://www.heartbeam.com/indications. The full press release is available at https://ibn.fm/ainxV.
